Isoform-Specific Divergent Roles of Class I HDACs in Cardiac Hypertrophic Remodeling
DOI:
https://doi.org/10.54097/176fb211Keywords:
cardiac hypertrophy, Class I HDAC, knockdown, siRNA.Abstract
Class I histone deacetylases are emerging targets to manage cardiac hypertrophy. To delineate their individual roles, we used siRNA to knock down each HDAC isoform in human AC16 cardiomyocytes, in the presence or absence of angiotensin II (AngII). We found that HDAC1 and HDAC3 silencing could effectively reduce MYH7 expression and partially reverse cellular enlargement, whereas HDAC2 knockdown surprisingly exacerbated hypertrophy. Cross-isoform compensatory effects were also observed. RNA sequencing revealed distinct gene regulation profiles driven by different HDAC inhibitions. These results suggest that Class I HDAC isoforms mediate distinct, sometimes opposing, effects on cardiac hypertrophy.
Downloads
References
[1] Burkart, V., Kowalski, K., Disch, A., Hilfiker-Kleiner, D., Lal, S., Remedios, C. dos, Perrot, A., Zeug, A., Evgeni Ponimaskin, Kosanke, M., Dittrich-Breiholz, O., Kraft, T., & Montag, J. (2023). Nonsense mediated decay factor UPF3B is associated with cMyBP-C haploinsufficiency in hypertrophic cardiomyopathy patients. Journal of Molecular and Cellular Cardiology, 185, 26–37. https://doi.org/10.1016/j.yjmcc.2023.09.008 DOI: https://doi.org/10.1016/j.yjmcc.2023.09.008
[2] Chidiac, P., Sobiesiak, A. J., Lee, K. N., Gros, R., & Nguyen, C. H. (2014). The eIF2B-interacting domain of RGS2 protects against GPCR agonist-induced hypertrophy in neonatal rat cardiomyocytes. Cellular Signalling, 26(6), 1226–1234. https://doi.org/10.1016/j.cellsig.2014.02.006 DOI: https://doi.org/10.1016/j.cellsig.2014.02.006
[3] Dupuis, L. E., Berger, M. G., Feldman, S., Doucette, L., Fowlkes, V., Chakravarti, S., Thibaudeau, S., Alcala, N. E., Bradshaw, A. D., & Kern, C. B. (2015). Lumican deficiency results in cardiomyocyte hypertrophy with altered collagen assembly. Journal of Molecular and Cellular Cardiology, 84, 70–80. https://doi.org/10.1016/j.yjmcc.2015.04.007 DOI: https://doi.org/10.1016/j.yjmcc.2015.04.007
[4] Gillette, T. G. (2021). HDAC Inhibition in the Heart: Erasing Hidden Fibrosis. Circulation, 143(19), 1891–1893. DOI: https://doi.org/10.1161/CIRCULATIONAHA.121.054262
[5] Gillette, T. G., & Hill, J. A. (2015). Readers, Writers, and Erasers. Circulation Research, 116(7), 1245–1253. https://doi.org/10.1161/circresaha.116.303630 DOI: https://doi.org/10.1161/CIRCRESAHA.116.303630
[6] Haberland, M., Mokalled, M. H., Montgomery, R. L., & Olson, E. N. (2009). Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes & Development, 23(14), 1625–1630. https://doi.org/10.1101/gad.1809209 DOI: https://doi.org/10.1101/gad.1809209
[7] Kee, H. J., Sohn, I. S., Nam, K. I., Park, J. E., Qian, Y. R., Yin, Z., Ahn, Y., Jeong, M. H., Bang, Y.-J., Kim, N., Kim, J.-K., Kim, K. K., Epstein, J. A., & Kook, H. (2006). Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic Banding. Circulation, 113(1), 51–59. https://doi.org/10.1161/circulationaha.105.559724 DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.559724
[8] Kong, Y., Tannous, P., Lu, G., Berenji, K., Rothermel, B. A., Olson, E. N., & Hill, J. A. (2006). Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy. Circulation, 113(22), 2579–2588. https://doi.org/10.1161/circulationaha.106.625467 DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.625467
[9] Kouzu, H., Tatekoshi, Y., Chang, H.-C., Shapiro, J. S., McGee, W. A., Jesus, A. D., Ben-Sahra, I., Arany, Z., Leor, J., Chen, C., Blackshear, P. J., & Ardehali, H. (2022). ZFP36L2 suppresses mTORc1 through a P53-dependent pathway to prevent peripartum cardiomyopathy in mice. Journal of Clinical Investigation, 132(10). https://doi.org/10.1172/jci154491 DOI: https://doi.org/10.1172/JCI154491
[10] Morales, C. R., Li, D. L., Pedrozo, Z., May, H. I., Jiang, N., Kyrychenko, V., Cho, G. W., Kim, S. Y., Wang, Z. V., Rotter, D., Rothermel, B. A., Schneider, J. W., Lavandero, S., Gillette, T. G., & Hill, J. A. (2016). Inhibition of class I histone deacetylases blunt cardiac hypertrophy through TSC2-dependent mTOR repression. Science Signaling, 9(422). https://doi.org/10.1126/scisignal.aad5736 DOI: https://doi.org/10.1126/scisignal.aad5736
[11] National Center for Cardiovascular Diseases, The Writing Committee of the Report on Cardiovascular Health and Diseases in China. (2024). Report on Cardiovascular Health and Diseases in China 2023: An Updated Summary. PubMed, 37(9), 949–992. https://doi.org/10.3967/bes2024.162
[12] Suddason, T., & Gallagher, E. (2015). A RING to rule them all? Insights into the Map3k1 PHD motif provide a new mechanistic understanding into the diverse roles of Map3k1. Cell Death & Differentiation, 22(4), 540–548. https://doi.org/10.1038/cdd.2014.239 DOI: https://doi.org/10.1038/cdd.2014.239
[13] Yan, G., Zhu, N., Huang, S., Yi, B., Shang, X., Chen, M., Wang, N., Zhang, G., Talarico, J. A., Tilley, D. G., Gao, E., & Sun, J. (2015). Orphan Nuclear Receptor Nur77 Inhibits Cardiac Hypertrophic Response to Beta-Adrenergic Stimulation. Molecular and Cellular Biology, 35(19), 3312–3323. https://doi.org/10.1128/mcb.00229-15 DOI: https://doi.org/10.1128/MCB.00229-15
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
